|
Genesis of the Next Era
The world of life sciences and bio-innovation continues to evolve, possibly faster than ever, as new technological, geographical and business trends emerge. That is why excitement is building for Genesis 2025 in London in just four weeks’ time. The unique forum, heading into its 25th edition, will debate the changing financing landscape, the new technologies having an impact on R&D, lessons from advances in rare diseases and what to do when partnerships don’t work out.
How the expert panels delve into some of the more challenging as well as most exciting aspects of these topics is highly anticipated. Further, there will be the new company showcase of 50 pitches and, absolutely, a nod to this milestone year as we look at how medicines will be developed in 2050 and consider whether the past 25 years of bio-innovation have delivered on expectations.
Collaborate to Innovate – London Bio-innovation Week
The opportunities are not limited to the main day of Genesis. The future will be driven by the combination of world-class research, investors in the resulting innovation and partnerships. The road to better patient outcomes in the future is a journey from discovery to deployment. Like the Tour de France, it is a journey of many and varied stages, each requiring different skills and approaches in a team effort if success is to be achieved. Bringing those playing critical roles in the Tour de Biomedicine is the exciting collaboration between ELRIG, SLAS, Life Science Integrates, Life Science Nation (LSN) and One Nucleus to build the inaugural London Bio-Innovation Week (#LBW25) across four leading events with the ability for all to connect on the app.
Be Informed to be Prepared
We all know how the saying 'Fail to prepare…' ends, and likely we have all been guilty of falling foul of it more times than we would like. Looking beyond the passion and excitement of innovation and new things, life science businesses need to consider a plethora of key business compliance, strategies and adaptations to succeed in the global life science industry. Below are recent highlights from key roundtable discussions organised by One Nucleus that every entrepreneur and business leader should note. Moreover, readers will also see links to the announcement that the Biomedical Catalyst funding competition is reopening and insights into claiming overseas R&D costs tax credits.
Staying Up-to-date
Remain informed of all One Nucleus updates, disseminate your company’s news, or track the announcements from other members, and make full use of our website, LinkedIn, or X pages. The news stream contains numerous updates from our community. Enjoy the read!
Tony Jones
••••••••••••••••••••••••••••••••••••••••
One Nucleus Highlights Autumn/Winter 2025 is Live
Sponsored by Catalent
![]() 
The twice-yearly One Nucleus Highlights publication was released this week featuring a review of some of One Nucleus' key achievements, several thought leadership articles from One Nucleus members, updates on One Nucleus staff and board changes, details of the membership benefits available and an advance look at what is coming up in 2026. Read the full publication here.
The Life Science Nation Effect
Accessing capital has rarely been more challenging for life science companies, especially early-stage ones, than in recent years. There are encouraging signs of risk investment returning, and 2025 is set to be a record year for M&A and licensing deals, so perhaps a corner is being turned. Throughout the past decade, LSN, through its mentoring, business intelligence sharing and RESI conferences, has enabled early-stage companies to access global capital sources totalling in excess of $1Bn.
Moreover, their disruptive approach has demonstrated that whilst traditional venture capital steals the headlines, there are numerous other sources of innovation capital that can be tapped. One Nucleus has always resisted simply duplicating other events when it came to investment events unless it found something innovative to add to our ecosystem. RESI London was that innovative addition, and hence the strategic partnering between Genesis and RESI will again be delivered in London this December. Readers can check out this recent blog on the LSN success to date to gain insight into how their approach works.
Key Insights for Life Science Company Leaders
It would be surprising if the excitement of doing groundbreaking science, signing the latest deal, or presenting the progress made was not the energy source driving life science business leaders. However, there are other, perhaps deemed less exciting but equally valuable insights required to build a resilient and investable company. One Nucleus seeks to bring these to our members also, given their importance through Special Interest Groups, thought leadership articles from members and peer-to-peer connectivity. Recently there have been three such insight roundtables that each revealed pointers all should have on their radar as follows, where you will find links to the associated slide decks:
- Evolving Challenges of Cross-Border Expansion – delivered by 39 Essex Chambers and Pinsent Masons – slides available HERE
- Aligning with FDA Incentive Programmes – delivered by Orrick – slides available HERE
- Transforming Biotech with AI – delivered by Penningtons Manches Cooper, Partners& and Freeman Clarke – slides available HERE
Claiming R&D Tax Credits for Overseas Expenditure
The reform of the R&D Tax Credit system made the default position ‘UK only’ when it came to what expenditure could be counted. For life science companies, going ex-UK may be the only reasonable option; however, so what are the exceptions. LimestoneGrey provides some expert guidance.
The UKRI BioMedical Catalyst 2025 Opens 10 November
It feels like the return of an old friend for early-stage companies, but at last the BioMedical Catalyst is back for both Industry-Led R&D Small Projects and Industry-Led R&D Large Projects.
Fisher Scientific Equipment End of Year Sale
![]() 
|
